Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2018-03-06

FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Steglujan (ertugliflozin and sitagliptin) from Merck Sharp & Dohme LLC, indicating changes to the product labeli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN)

Snippet

SUPPL AP for STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN)